Clinical trial NCT03862430: A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Official title: A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Glioblastoma Multiforme
Lead sponsor: NuvOx LLC
Sponsor class: INDUSTRY
First posted: 2019-03-05
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy.

NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.

Detailed description: All study participants will receive standard care for GBM including Temozolomide and radiation therapy. Subjects will be randomized on a 2 to 1 basis to receive either NanO2 infusions or saline infusions immediately prior to standard radiation therapy. Radiation therapy is performed 5 days a week for 6 weeks.

Radiation therapy is followed 28 days of recovery, and then six cycles of maintenance Temozolomide therapy on days 1 to 5 of six 28 day cycles.

Follow up will be every 3 months for 3 years, and then every 6 months for another 2 years.

Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed, newly diagnosed primary or secondary glioblastoma multiforme.
2. Treatment plan includes 60 Gy of focal radiation administered in 30 fractions, concurrently with temozolomide chemotherapy.
3. Manageable risks associated with potential radiation necrosis in the radiation field, based on size of the field and proximity to eloquent brain regions (as assessed by the investigator).
4. Aged 18 years and older.
5. Karnofsky Performance Status ≥ 70
6. Life expectancy of at least 3 months.
7. Able to undergo gadolinium-enhanced MRI (Gd-MRI) scans.
8. Baseline MRI performed within 7 days before starting study treatment while on a stable or decreasing glucocorticoid dose for at least 7 days before and during the imaging study.
9. Adequate hematologic, renal and hepatic function, as defined by:

   1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
   2. Platelet count ≥ 75 x 109/L
   3. Hemoglobin ≥ 10.0 g/dl
   4. Serum creatinine \< 1.5 x ULN
   5. Total bilirubin within normal limits (≤ 2.5 x ULN if Gilbert's syndrome)
   6. Aspartate transaminase (AST) and Alanine transaminase (ALT) \< 2.5 x ULN
10. Women of childbearing potential or men with child-bearing potential partners (unless vasectomized) must agree to use a highly-effective method of birth control from study entry until 4 months after completing study therapy.
11. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

1. Recurrent Glioblastoma
2. Prior treatment for glioblastoma apart from surgical resection.
3. Presence of multi-focal glioblastoma disease that cannot be encompassed into a radiation treatment field that would be safely treated to the prescribed radiation dose.
4. Presence of leptomeningeal disease that cannot be encompassed within a feasible and safe radiation field.
5. Intracranial bleeding, except for stable grade 1 hemorrhage or a post-operative bleed that is clearing.
6. Has not recovered from the adverse effects of surgical resection or biopsy, except for neurological deficits.
7. Subjects who have received any other investigational agent within 4 weeks before enrollment
8. Stroke or transient ischemic attack requiring hospitalization within 6 months before enrollment.
9. Myocardial infarction (MI) within 6 months before enrolment, unstable angina, New York Heart Association (NYHA) class II or greater congestive heart failure, or uncontrolled hypertension (systolic BP \> 160 mmHg and/or diastolic BP \> 100 mmHg).
10. Known History of Congenital long QT syndrome (12-lead EKG is not required).
11. Clinically significant chronic obstructive pulmonary disease or asthma.
12. Active major infection requiring treatment.
13. A history of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancers or other solid tumors curatively treated with no evidence of disease for ≥ 2 years.
14. Known infection with human immunodeficiency virus or hepatitis B or C virus (testing is not required).
15. Current anticoagulant or antiplatelet therapy, except for prophylactic doses of low molecular weight heparins, low-dose aspirin, rivaroxaban (Xarelto®), apixaban (Eliquis®), or dabigatran (Pradaxa®).
16. History of allergic reactions attributed to compounds of similar chemical composition to NanO2.
17. Women who are pregnant or breast feeding.
18. Inability to comply with study procedures.
19. History or evidence of any other clinically significant condition that, in the opinion of the investigator, would pose a risk to subject safety or interfere with study procedures, evaluation or completion.
20. Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).

Primary outcomes:
measure: Progression-Free Survival (PFS)
timeFrame: 22 months
Secondary outcomes:
measure: Overall Survival
timeFrame: 22 Months
measure: Response assessment by mRANO
timeFrame: 22 Months
measure: Response assessment for pseudoprogression
timeFrame: 22 Months
measure: To confirm that NanO2 re-oxygenation
timeFrame: 22 Months
measure: To estimate the effect on the duration of functional independence
timeFrame: 22 Months
measure: Patient quality of life
timeFrame: 22 Months
measure: Caregiver quality of life
timeFrame: 22 Months
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Center for Neurosciences
state: Arizona
city: Tucson
country: United States
facility: University of Arizona
state: Arizona
city: Orange
country: United States
facility: UC Irvine Health- Chao Family Comprehensive Cancer Center
state: California
city: Santa Monica
country: United States
facility: Providence St. John's Cancer Institute
state: California
city: New Haven
country: United States
facility: Yale Cancer Center
state: Connecticut
city: Peoria
country: United States
facility: St. Francis Medical Center, OSF Healthcare
state: Illinois
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
city: Kansas City
country: United States
facility: Saint Luke's Cancer Institute
state: Missouri
city: Summit
country: United States
facility: Atlantic Health System
state: New Jersey
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Cleveland
country: United States
facility: University Hospitals Seidman Cancer Center
state: Ohio
city: Fairfax
country: United States
facility: Inova Schar Cancer Institute
state: Virginia
Study officials:
References: